Immutep's LAG-3 drug 'dramatically undervalued,' says analys...

Australian biotech Immutep's LAG-3 checkpoint inhibitor eftilagimod alpha (efti) may not be the first drug in the class to reach the market, but is a strong contender and, according to at l